ANN ARBOR, Mich., – October 2, 2023 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, today announced a shakeup of the management of its Vietnamese subsidiary, Prodigy Textiles (“Prodigy”). The changes in management personnel and the implementation of new procedures are intended to refocus and re-energize Prodigy, as the Company’s silkworm breeding and egg production/distribution center to support large-scale spider silk manufacturing.

These changes are part of the Company’s larger efforts to optimize operations and fulfill its vision to commercialize spider silk using its scalable, cost-effective, and eco-responsible technologies.

Prodigy’s day-to-day will be led by its new general manager under the supervision of Kraig Labs’ COO. Mr. Ken Le will retain his position as Prodigy Textiles Director, focusing on business development and government relations. The Company is also replacing Prodigy’s head of sericulture and onboarding industry expertise.

“These steps, designed to improve efficiencies and encourage innovation, were taken after thoroughly assessing Prodigy’s operations, procedures, and management,” said COO Jon Rice. “The spider silk technologies developed at Kraig Labs are ready for large-scale production. I am confident that the changes we are making at Prodigy will provide the platform for that growth.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward-Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward-looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

As many of you may know, our R&D headquarters is located near the center of a storm that saw seven separate tornados touch down on the evening of Thursday, August 24^th.   This storm caused significant power outages across the state, with hundreds of thousands of individuals affected and tens of thousands without power for more than three days, including our R&D headquarters.

I am very pleased to report that our team at Kraig Labs was prepared for this storm, immediately implementing our disaster preparedness plan, and was able to maintain all critical operations at our R&D headquarters throughout the storm and its aftermath. 

As a result of our teams’ quick actions, all critical genetic materials and transgenics are secure, and we remain on track to deliver the next generation of production hybrids to our third-party production partner as scheduled.  Our team maintained around-the-clock watch of our facility and our backup power systems throughout the weekend to ensure all critical systems remained online.  

In the coming weeks, we plan to share additional exciting details on the significant progress we’ve made in all core aspects of our business plan, from molecular biology to the status of our manufacturing operations in Vietnam and the coming roll-out of our next-generation recombinant spider silk hybrids. 

From all of us here at Kraig Labs, we wish you and yours a happy and safe Labor Day weekend.

   – – –

Kim Thompson, Founder and CEO

Kraig Biocraft Laboratories, Inc.

Last month Kraig Labs submitted its response to the U.S. Air Force Research Laboratories (AFRL) Request For Information (RFI) solicitation. This RFI sought out U.S. industrial supply base members that could help strengthen the country’s bio-engineering and bio-manufacturing sectors. This request was intended to ensure that the United States remains at the forefront of bio-manufacturing capabilities and to ensure a domestic supply base for future defense-related production capacity. 

In addition to the renewed interest from the U.S. Department of Defense for the domestic production of bio-engineered materials and manufacturing technologies, Kraig Labs has also been approached by the Ministry of Defense from one of our ally nations. They requested samples of our recombinant spider silk materials for evaluation in protective textile applications. 

The last few weeks have been a busy and exciting time for Kraig Labs and our research and development team. We welcomed several new staff members to our research and development team who are filling many diverse roles, from silkworm colony management to research and creation of the next generation of transgenics. We are still in the hiring process and anticipate adding one or two more qualified R&D team members over the next sixty days.

Our team is bustling as we continue to strengthen our operations through the introduction of more robust commercial silkworm background genetics. The work that we started in late 2022 with the first cross-hybrids, blending our spider silk technology with commercial silkworm strains, has now expanded to nearly a dozen strains of robust production silkworm lines. These strains were sourced from around the world and selected for their strong genetic background and cocoon performance. With these additional strains in-house, we are now starting to cross-breed our spider silk transgenes into these various commercial lines.

Over the next several months, we expect to create enough unique strains of spider silk transgenics to implement a multi-line “double hybrid” production system. We have already begun this process of breeding spider silk-producing variants of the first of these commercial strains that, when crossed with each other, should produce the largest and most robust production silkworms in the Company’s history. 

The program to increase robustness in our spider silk transgenics remains on track and is proceeding as scheduled. We expect to be able to announce the creation of several new lines of production spider silk strains as early as the third quarter.

Beyond the creation of additional robust production strains of our spider silk transgenics, our research team has been quietly working over the last months on multiple projects that we hope to begin sharing more details on soon.

As the research team works to advance the genetics and robustness of our silkworms for the production environment, the Company has also been working in collaboration with its textile consultant and yarn spinners to develop the first materials and applications for spider silk in textiles. The first of these yarns, designed in late 2022, has now been spun. After consultation with several mills, the Company successfully created the first composite silk, pima cotton yarns, with one of the world’s premier cotton spinners. This initial trial proved to be a great success, giving us great insight into aspects of blending silk and cotton that we have used to further refine our silk processing steps. 

Based on the technical analysis of the first silk and cotton composite yarn, the Company partnered with leading U.S. textile engineers to improve several aspects of the silk cutting, washing, and opening processes. The results are a set of processing steps and protocols that have proven to improve the silk staple fiber separation and alignment, which will increase the overall quality and uniformity of the composite yarns. To ensure the quality of these processes as we scale up production, we have invested in the production equipment necessary for the in-house manufacturing of silk staple fibers. These are essential processing steps done after the cocoons have been reeled into raw silk and before the silk can be blended and spun with other fibers. 

We have taken the detailed technical analysis from the spinning of the first yarn and revamped our staple fiber processing with the guidance and advice of top experts here in the U.S. We believe that perfecting the processing of the fibers and yarns which will, in turn, create fabrics and garments of the highest quality is critical for the launch of our joint venture apparel brand, SpydaSilk^TM.  Kraig Labs and our partner Kings Group have intentionally slowed down the marketing and launch of the SpydaSilk, the website, and its social media presence, to align with the future release of the brand’s first products.  

Many of you have asked, in recent months, about the near-term potential for an up-listing to a national exchange. Our focus is on building the Company and its fundamentals, most particularly larger scale production. The robustness of our silkworms in the production environment is now the largest bottleneck to large-scale production, and that is the reason for our emphasis on Mendelian genetics and hybridization. Management believes that it would be a miscalculation to attempt an up-list while experiencing a production bottleneck. The sooner we can create new strains and achieve large-scale production, the better for our fundamentals and for the prospect of moving to a larger exchange. 

Our focus remains on developing and improving the robustness of our silkworm strains that can sustain large-scale spider silk production and leveraging that to build a sustainable market presence for Kraig Labs, SpydaSilk, and other future partnerships.

A few shareholders raised questions about the high temperatures that Vietnam recently experienced. First, those record temperatures were set in Thanh Hoa province, more than 700km north of our facilities in Quang Nam. Prodigy Textiles has not experienced any record-setting local temperatures, and even if such climate abnormalities occur in the future, it is equipped to handle them. Prodigy Textiles operates from a historical silk breeding facility constructed with double-insulating brick and concrete walls to regulate temperatures inside. When we renovated the facility, we added air processing and conditioning equipment to all of our rearing facilities to ensure tight control of climate conditions in our egg breeding center, allowing year-round operation. This heat wave also hit the country while our third-party contractor has paused their operations as they await the delivery of more robust silkworms from our teams here at Kraig and Prodigy. The increased robustness that we are building into our transgenics through the global sourcing of commercial silkworm genetics should strengthen their operations for climate variances and disease resistance.

As our team works to eliminate the current production bottleneck by improving background genetics through cross-breeding and hybridization, another emphasis is on creating new transgenics for the production of more advanced materials.   Those two main thrusts of our operation are the reason behind the expansion of our R&D staff. We are excited about the progress we have made internally over the last quarter, and we are very excited to see the continuing progress we are making on enhancing background genetics. 

I want to thank our R&D team for their dedication to this work and I also want to thank our team at Prodigy as well as our contractors for their insights on production. Production is our goal; production is our focus. Production is the key to our fundamentals and all the opportunities that lay ahead. 

   – – –

Kim Thompson, Founder and CEO

Kraig Biocraft Laboratories, Inc.

ANN ARBOR, Mich., – April 5, 2023 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces today that it is preparing a response to the United States Air Force under the Defense Production Act Investments (DPAI) program. In its efforts to strengthen the U.S. bio-industrial manufacturing capabilities, the U.S. Government is seeking input from industry to identify target areas for governmental investment. 

Under the 2023 National Defense Authorization Act and through executive order, the Secretary of Defense has been authorized to “incentives the expansion of domestic, flexible industrial biomanufacturing capacity for a wide range of materials.” Biosynthetic fibers such as spider silk were specifically identified as a material/technology of interest under this directive. 

Kraig Labs is preparing a detailed response for submission to the U.S. Air Force by its April 19 deadline. While this request for information does not guarantee a subsequent request for proposal or that funding will be available, it does signify the importance that materials, such as spider silk, can play both economically and defensively.   

“We are very pleased to see the renewed support and interest from the Department of Defense (DoD) to strength the U.S. industry supply base for bio-engineering and bio-manufactured materials,” said Company COO Jon Rice. “I believe that Kraig Labs is and will remain a key player in our domestic biomanufacturing capabilities, and we welcome the opportunity to bring the DoD up to date with our progress and the opportunities that lie ahead.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – February 28, 2023 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces today that it has created and seeks to fill two new senior-level genetic engineering positions within its U.S. based research and development team. These new roles will expand and strengthen the research team’s capabilities in order to accelerate the pace of development for the next generation of spider silk technologies. 

These new roles will significantly expand the current research team’s development throughput. This in turn will allow for the acceleration of numerous designs for fibrous and non-fibrous spider silk protein concepts, currently on the drawing board, to be developed into working materials and production.

“We currently have numerous new material concepts and opportunities for spider silk on the drawing board. Bringing on additional senior-level researchers should provide our team with the additional technical support and assistance needed to advance these concepts into new transgenics and materials,” said Company COO Jon Rice. “This is an exciting time for the Company and our R&D team as we look to accelerate the timing for transitioning new spider silk concepts from the lab into production.”

Highly qualified candidates are encouraged to apply via the job posting on Indeed or by clicking here

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Ann Arbor, MI – January 26, 2023– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has delivered the first two hybrid-cross Dragon Silk^TM strains to its third-party production partner in Vietnam. These strains were developed to address the most significant immediate hurdle to large-scale production, the robustness of our silkworms within the large-scale production environment. These new lines are the first of several planned silkworm strains in our hybridization program, which are explicitly designed to increase robustness and cocoon size. 

These strains blend the mechanical performance of the Company’s original Dragon Silk with the size and robustness of native production silkworm strains. The Company engineered these strains as part of its development program to bring needed increased resiliency to the large-scale production environment. 

Best practices employed by the most advanced silkworm egg production facilities include utilizing a multi-line cross-mating protocol to generate increased robustness. The result of first-generation cross-matings yield larger cocoons and more resilient silkworm offspring. As these increased performance attributes only last one generation, it is vital that central silkworm egg production operations sustain each of these separate lines in order to create successive generations of hybrid crosses. 

Kraig Labs begins its transition to multi-line cross-mating with these two new hybrids. Once established at the production facilities, the Company will start cross-matings to produce our first two-line production hybrids. Kraig Labs believes this will strengthen its production operations, increase silkworm resiliency, and significantly improve environmental tolerance.  

As part of the Company’s ongoing development efforts to commercialize spider silk production, it is also developing a four-line hybrid-cross program that should further improve yields. This program is under development at the Company’s R&D headquarters located in the USA and is planned to begin rollout in stages later this year following the successful implementation of the two-line hybrid-cross model.

“Work with our production partner in Vietnam has accelerated the identification of challenges and opportunities in scaling up production to metric tonnage levels,” said Company COO Jon Rice. “We are very pleased to announce the delivery of these new hybrid lines and we are excited about our ongoing development of the four-line hybrid-cross. The implementation of the four-line hybrid program is designed to deliver significant improvements in production capacity and yield.”Top of FormBottom of Form

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “should,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Ann Arbor, MI– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has nearly closed out its $8 million in convertible debenture with Yorkville Advisors. Over the last 23 months, the Company has converted more than 98% of this debt to equity. Kraig Labs remains in one of the strongest financial positions in the Company’s history, with more than $4.5 million in liquid assets and a remaining debt balance to Yorkville of only $150,000. 

The capital raised through this financing has been deployed in building out the Company’s in-house production and laboratory facilities in Vietnam, expanding the capabilities and research focus of our US-based R&D center, and funding the Company’s work with third-party production partners to scale up spider silk production. Looking forward, the Company expects to continue investing in the scale-up of production capacity, pioneering innovations in spider silk technologies, and bringing products to end markets through direct sales and strategic partnerships.

“Due to the significant progress that we made in securing our new production partnership program, which is designed to allow Kraig Labs to meet anticipated demand without the previous model’s intense capital investments, these funds provide us the flexibility that we need to continue to drive growth and strengthen our operations from R&D through finished products,” said Company COO, Jon Rice.

“With more than $4.5 million of immediately deployable capital and having nearly eliminated the balance on this debit financing, Kraig Labs has never been in a stronger financial position. We will continue to strategically invest this capital in ramping production through our in-house capacity and partnership with our third-party contractor as well as launch the next generations of hybrid spider silk technologies,” Rice concluded.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Ann Arbor, Michigan., – July 18, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the signing of its first 3^rd party production contract for large scale manufacturing of the Company’s recombinant spider silk. The Company expects to immediately begin operations with this contractor producing hundreds of kilograms of spider silk per month and to achieve production levels reaching multiple metric tons of spider silk per month as early as the first quarter of 2023. The contractor is in possession of the Company’s specialized eggs and anticipates a 90-day ramp-up for the first deliveries under the contract.

Pilot testing with this contractor during the first two quarters of 2022 demonstrated the capacity and expertise of this manufacturer to operate at a large scale and with excellent quality.

Under the contract terms, Kraig Labs will become a minority owner of the silk producer. Kraig Labs will have complete access to the manufacturer’s financial records and an onsite presence to ensure the proper handling and security of the Company’s propriety spider silk technology.

“Our business model was designed to leverage the existing silk production infrastructure. The signing of this agreement rapidly expands our access into that production network and brings us to the next critical stage in our business plan,” said Company COO Jon Rice. “Working with this contract manufacturer, we will soon be ready to deliver metric tons of eco-responsible and cost-effective spider silk to the consumer markets.”

In the coming days, the Company plans to release the first in a series of behind-the-scenes videos looking into its operations in Vietnam and the commercialization of its spider silk materials.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Ann Arbor, MI – July 6, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has produced several new lines of larger hybrid Dragon Silk^TM silkworms for its production operations in Vietnam. These new breeds of silkworms were explicitly created for large-scale production. 

With a larger cocoon and longer silk filament, these optimized Dragon Silk breeds reduce production costs and increase throughput.

The new breeds were created using a process of hybridization, combining the best properties of Dragon Silk with the best practices in silkworm breeding to improve the size and robustness of the silkworm strain. Commonly used in commercial mundane silk production, the process of creating these production hybrid silkworms delivers between 30-100% larger silk cocoons than non-hybridized silkworms.

The Company first began the development of large cocoon hybrids in 2018. The success of that effort is the foundation of today’s announcement and the rollout of this technology into production. Commercializing this technology required the Company to develop multiple strains of Dragon Silk hybrids that, when paired together, deliver a consistent and scalable large cocoon production platform.

“The hybridization program was a key part of the Company’s technology roadmap and something our R&D team has been quietly working on behind the scenes,” said Company COO Jon Rice. “Today, we announce that this technology is in the factory. This technology will lower our operating costs from rearing all the way through silk reeling and spinning. Over the coming months, our production team will transition egg production to this new, larger Dragon Silk line.”

Accelerating the transition of these new larger breeds of Dragon Silk to production was driven by the Company’s success with 3^rd party contract production and our rapidly growing demand for increased quantities of Dragon Silk.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – May 17, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the first sample shipment of its recombinant spider silk fibers and fabrics for use and evaluation into a range of biomedical applications. This shipment was made in response to the significant increase in the requests for its propriety spider silk technology over the last two quarters for tissue engineering applications.

Aided by its unique blend of mechanical and chemical properties, spider silk has long been recognized as an ideal natural biomaterial. As a lightweight, biocompatible, and biodegradable material, spider silk applications have been tested in numerous morphologies, including; fibers, films, hydrogels, non-woven fabrics, foams, etc. While the first known uses of spider silk as a suture date back to the 18^th century, limitations in the production and costs of spider silk have prevented its broad adoption.

Kraig Labs’ revolutionary approach creating recombinant spider silk technology utilizing genetically enhanced silkworms unlocks the door for large-scale adoption of spider silk for biomedical applications. This system merges the performance of spider silk with the well-established, large-scale supply chain for mundane silk.

With the growth of its production operations in Vietnam over the last two quarters, the Company is now positioned to allot a portion of its spider silk production to address the medical community’s needs. This week’s shipments are just the first in what the Company hopes will be a significant mid to long-term market growth opportunity for Kraig Labs and its foray into the growing field of bioengineering.

“Over the last month, we have seen a significant increase in the demand from the medical field for our spider silk fibers and fabrics,” said COO Jon Rice. “With the great work our team in Vietnam has done increasing monthly silk production, we are now positioned to begin supplying R&D samples for this new and exciting end market. As these applications often require FDA approval, we believe the biomedical space has the potential to play an important role in the long-term growth of the Company. Over the coming months we will be closely monitoring the results of these first tests and assessing additional opportunities for the spider silk gels and films we have already developed into the broad field of biomaterials.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com